Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bibeau

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Histopathology|April 10, 2008
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesionsG MacGrogan, L Arnould, I de Mascarel, et al.
British Journal of Cancer|April 16, 2009
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyA Oden-Gangloff, F Di Fiore, F Bibeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Oncogene|May 21, 2008
Lobular and ductal carcinomas of the breast have distinct genomic and expression profilesF Bertucci, B Orsetti, V Nègre, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 30, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapyS Cherradi, A Ayrolles-Torro, N Vezzo-Vié, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 17, 2017
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE studyS Valmary-Degano, P Colpart, L Villeneuve, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiencyR Cohen, O Buhard, P Cervera, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Oncogene|July 26, 2011
A refined molecular taxonomy of breast cancerM Guedj, L Marisa, A de Reynies, et al.
Virchows Archiv : an International Journal of Pathology|February 8, 2019
National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016C Boutanos, M Capdepont, M Svrcek, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Histopathology|April 10, 2008
Impact of immunohistochemical markers, CK5/6 and E-cadherin on diagnostic agreement in non-invasive proliferative breast lesionsG MacGrogan, L Arnould, I de Mascarel, et al.
British Journal of Cancer|April 16, 2009
TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapyA Oden-Gangloff, F Di Fiore, F Bibeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialE Munzone, A Giobbie-Hurder, B A Gusterson, et al.
Oncogene|May 21, 2008
Lobular and ductal carcinomas of the breast have distinct genomic and expression profilesF Bertucci, B Orsetti, V Nègre, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 30, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapyS Cherradi, A Ayrolles-Torro, N Vezzo-Vié, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 17, 2017
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE studyS Valmary-Degano, P Colpart, L Villeneuve, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiencyR Cohen, O Buhard, P Cervera, et al.
British Journal of Cancer|January 11, 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trialE Samalin, O Bouché, S Thézenas, et al.
Oncogene|July 26, 2011
A refined molecular taxonomy of breast cancerM Guedj, L Marisa, A de Reynies, et al.
Virchows Archiv : an International Journal of Pathology|February 8, 2019
National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016C Boutanos, M Capdepont, M Svrcek, et al.
Pageof 5